Fluoxetine for Major Depressive Disorder

What research says

EveryOption research summary

The retained fluoxetine label reports placebo-controlled studies for major depressive disorder; this assessment does not determine personal suitability or compare fluoxetine with every alternative.

See sourceDailyMed fluoxetine hydrochloride label · checked Oct 16, 2026

Source for the opening statement

Relationship: supports bounded conclusion

This statement’s scope

Population: source-defined study populations

Published supporting passage

The efficacy of fluoxetine was studied in 5- and 6-week placebo-controlled trials with depressed adult and geriatric outpatients (≥ 18 years of age) whose diagnoses corresponded most closely to the DSM-III (currently DSM-IV) category of MDD.

All published source details

Population: source-defined study populations
Jurisdiction: United States label
Need: Major Depressive Disorder

Source collection coverage: country:US
Source pointer: /sections/4

Open published source

EveryOption’s published assessment

Research suggests benefit in this exact scope

Published Sep 20, 2026 · revision 1

Find care

Choose a place to see published offerings. A listing does not confirm current availability.

Choose a place Compare published Treatments for this Need

Why this Treatment appears for this Need

Why this Treatment appears in the Need landscape, separate from the research conclusion.

See relationship sourceDailyMed fluoxetine hydrochloride label · checked Oct 16, 2026

Relationship: label-reported clinical studies for the Need